Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Share-based Compensation (2016 - 2025)

Vistagen Therapeutics' Share-based Compensation history spans 14 years, with the latest figure at $1.1 million for Q4 2025.

  • For Q4 2025, Share-based Compensation rose 1.48% year-over-year to $1.1 million; the TTM value through Dec 2025 reached $4.1 million, up 5.09%, while the annual FY2025 figure was $4.3 million, 97.75% up from the prior year.
  • Share-based Compensation for Q4 2025 was $1.1 million at Vistagen Therapeutics, roughly flat from $1.1 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $1.2 million in Q2 2024 and bottomed at $490200.0 in Q1 2021.
  • The 4-year median for Share-based Compensation is $916000.0 (2025), against an average of $835853.8.
  • The largest annual shift saw Share-based Compensation plummeted 62.32% in 2021 before it skyrocketed 113.02% in 2024.
  • A 4-year view of Share-based Compensation shows it stood at $764500.0 in 2021, then plummeted by 33.68% to $507000.0 in 2023, then soared by 113.02% to $1.1 million in 2024, then grew by 1.48% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for VTGN's Share-based Compensation are $1.1 million (Q4 2025), $1.1 million (Q3 2025), and $916000.0 (Q2 2025).